MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), formerly, ISIS Pharmaceuticals*
Organization & Developments: Ionis
Parents
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), formerly, ISIS Pharmaceuticals*
Children
*Isis Pharmaceuticals (NASDAQ: ISIS)-#3 (Biotech-Patent Board-2007),
2015: Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals
2018: Ionis Leaping To All-Time Highs - More To Come? - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
2018: Ionis, Akcea team face some tough questions on safety as FDA insiders ponder risks linked to volanesorsen – Endpoints News
2018: Ionis: Performs Great In A Volatile Market - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
2018: Ionis: Superb Neurological Pipeline With 5 Additional Pipelines Of Note - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
2018: License deal where Akcea will have rights to commercialize inotersen and AKCEA-TTR-LRx globally. Akcea will pay Ionis an upfront fee of $150m, payable in shares.
2019: IBD Stock Of The Day Obliterates Earnings Views And Eyes New Buy Point_www.investors.com
2019: Ionis Pharmaceuticals And IONIS-GHR-LRx In Acromegaly_seekingalpha.com
2019: Ionis Pharmaceuticals: Platform Technology Play With Multiple Irons In The Fire - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
2019: Is This 'Perennial' Innovator Making A Comeback Among Biotech Stocks?_www.investors.com
2020: Ionis Is A Long On Neurological Medicines Pipeline
2020: Ionis Pharmaceuticals (IONS): Just A Few Short Hand Notes
2020: Ionis With Akcea: Still A Bargain
2020: Ionis: Opening Door To New Neurology Treatment Options
2020: Will These Biotechs Rival A Top-Notch Stock In High Triglycerides?_www.investors.com
2021: Ionis Pharmaceuticals: Recent Setback Offers An Interesting Opportunity
2022: Ionis Pharmaceuticals (NASDAQ:IONS) _seekingalpha.com
2022: Ionis Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2023: Ionis: Opportunity Abounds_ seekingalpha.com
2024: EU committee recommends AstraZeneca’s Wainzua for ATTRv-PN
2024: FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
2024: Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
2024: Ionis Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling
2024: Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval
2024: Ionis Pharmaceuticals' SWOT analysis: RNA pioneer's stock faces pivotal year
2024: Ionis: Expect More Of The Same In Terms Of Earnings, Despite Regulatory Successes
2024: Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
2025: Granted Breakthrough Therapy designation to ION582 for the treatment of Angelman syndrome (AS), a rare neurological disease that often presents in infancy and is characterized by profound intellectual disability, impaired communication, motor impairment and debilitating seizures.
2025: Ionis drug lowers triglycerides, reduces pancreas damage in late-stage studies
2025: Ionis gains FDA approval for RNA therapy donidalorsen for hereditary angioedema
2025: Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight
2026: 'It’s going to be huge': The 'diabolical' molecule poised to become biotech's next gold rush _ Lower lipoprotein(a)—abbreviated as Lp(a)
2026: GSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive disease
Jumps
*Key People: Ionis
Finance & Acquisition: Ionis